Evidence map›Paper›PMID 37615752›Full record

ReviewJournal of neurology2023

Risk factors for migraine disease progression: a narrative review for a patient-centered approach.

Richard B Lipton, Dawn C Buse, Stephanie J Nahas, Gretchen E Tietjen, Vincent T Martin, Elin Löf, Thomas Brevig, Roger Cady, Hans-Christoph Diener

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06304675 (Manageable Environmental Factors Affect Treatment Response as Much as Migraine Phenotype), which is not on this map. Cited by 62 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06304675 completednot on this map

Manageable Environmental Factors Affect Treatment Response as Much as Migraine Phenotype

Typeobservational_patient_registrySponsorSamsun UniversityRan2023 to 2024Enrolled500ConditionsMigraineArmsno intervention
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Lack of association between TRPV1 gene polymorphisms and risk of migraine chronification: a case-control study and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Parental knowledge, attitudes, and behaviors toward childhood headache: the impact of parental migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richard B LiptonDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-2652-2897
Dawn C BuseDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Stephanie J NahasDepartment of Neurology, Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8846-8393
Gretchen E TietjenUniversity of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID http://orcid.org/0000-0003-0524-5683
Vincent T MartinUniversity of Cincinnati Headache and Facial Pain Center, Cincinnati, OH, USA.
Elin LöfH. Lundbeck A/S, Copenhagen, Denmark.
Thomas BrevigH. Lundbeck A/S, Copenhagen, Denmark.
Roger CadyLundbeck LLC, Deerfield, IL, USA.
Hans-Christoph DienerInstitute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany. hans.diener@uk-essen.de.ORCID http://orcid.org/0000-0002-6556-8612

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn individuals with migraine, attacks may increase in frequency, severity, or both. Preventing migraine progression has emerged as a treatment goal in headache subspecialty practice, but there may be less awareness in general neurology or primary care settings where most people with migraine who seek treatment consult. Herein, we review the definition of and risk factors for migraine progression and consider strategies that could reduce its risk.

methodsA group of headache expert healthcare professionals, clinicians, and researchers reviewed published evidence documenting factors associated with increased or decreased rates of migraine progression and established expert opinions for disease management recommendations. Strength of evidence was rated as good, moderate, or based solely on expert opinion, using modified criteria for causation developed by AB Hill.

resultsMigraine progression is commonly operationally defined as the transition from ≤ 15 to ≥ 15 monthly headache days among people with migraine; however, this does not necessarily constitute a fundamental change in migraine biology and other definitions should be considered. Established and theoretical key risk factors for migraine progression were categorized into five domains: migraine disease characteristics, treatment-related factors, comorbidities, lifestyle/exogenous factors, and demographic factors. Within these domains, good evidence supports the following risk factors: poorly optimized acute headache treatment, cutaneous allodynia, acute medication overuse, selected psychiatric symptoms, extra-cephalic chronic pain conditions, metabolism-related comorbidities, sleep disturbances, respiratory conditions, former/current high caffeine intake, physical inactivity, financial constraints, tobacco use, and personal triggers as risk factors. Protective actions that may mitigate migraine progression are sparsely investigated in published literature; our discussion of these factors is primarily based on expert opinion.

conclusionsRecognizing risk factors for migraine progression will allow healthcare providers to suggest protective actions against migraine progression (Supplementary Fig. 1). Intervention studies are needed to weight the risk factors and test the clinical benefit of hypothesized mitigation strategies that emerge from epidemiological evidence.

Indexed as

Migraine DisordersChronic DiseaseDisease ProgressionHeadacheHumansPatient-Centered CareRisk FactorsChronic migraineEpisodic migraineMigraine progressionPrevention strategiesRisk factors

Identifiers

PMID37615752
PMCPMC10632231

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.